ANIMAL CORE: PHARMACOKINETICS, IMAGING AND THERAPY

CORE D CORE董事：ColCher，David首席研究员：RaubitSChek安德鲁 说明： 核心D是动物核心：药代动力学、成像和治疗。这个核心的主要功能是支持 项目1所用临床试剂动物模型质量控制研究 项目2中开发的肿瘤靶向放射性标记结构和基于抗体的免疫疗法 在项目3的多个模型系统中。这些药物将在生物分布和治疗方面进行评估。 研究以及使用COH提供的先进的动物成像仪器，其中 恰如其分。具体职能是：1)提供所需的设施和专业知识，以评估 以抗体为基础的构建物在小动物体内的生物分布和成像；以及2)进行研究 分析基于抗体的放射性标记构建物的药代动力学和治疗效果 模型系统中的免疫疗法。Core还将评估在Core C中准备的用于临床的材料 在项目1和3中使用。 核心D是项目1、2和3的关键组成部分。所有抗体构建都将在体外和在 移植到临床之前的活体。体内分析将作为此核心的一部分使用 核心人员的专业知识。动物的生物分布和成像研究将使用 核心人员，根据需要从个别项目中获得帮助。体内研究将需要获得 研究动物保护委员会，并将于#年在希望之城动物资源中心演出 潘/in大楼。本核心将评估多步靶向方法、多肽连接物和新的 用Fl1n、1251、1311、1“L_u、90Y、^Cu或124I标记后，在项目2中开发了抗体螯合结合物。

Core D Core Director: ColCher, David Principal Investigator: RaubitSChek. Andrew DESCRIPTION: Core D is the Animal Core: Pharmacokinetics, Imaging and Therapy. This core's main function is to support the quality control studies in animal models of the clinical reagents used in Project 1, the development of the tumor targeted radiolabeled constructs developed in Project 2 and the antibody based immunotherapeutics in Project 3 in a number of model systems. The agents will be evaluated in both biodistribution and therapy studies as well as by using the advanced animal imaging instrumentation available at the COH, where appropriate. The specific functions are: 1) To provide the needed facilities and expertise for evaluating the biodistribution and imaging of antibody based constructs in small animals; and 2) To perform studies to analyze the pharmacokinetics and therapeutic efficacy of antibody based radiolabeled constructs and immunotherapeutics in model systems. The Core will also evaluate materials prepared in Core C for clinical use in Projects 1 and 3. Core D is a critical component of Projects 1, 2 and 3. All antibody constructs will be evaluated in vitro and in vivo prior to translation into the clinic. The in vivo analysis will be performed as part of this Core using the expertise of the Core's personnel. Animal biodistribution and imaging studies will be performed using the Core personnel with help as needed from the individual projects. The in vivo studies will require approval by the Research Animal Care Committee and will be performed in the City of Hope Animal Resource Center in the Pan/in building. This Core will evaluate the multi-step targeting methods, peptide linkers and novel antibody chelate conjugates developed in Project 2 after labeling with fl1ln, 1251,1311,1"l_u, 90Y, ^Cu,or 124I.